Evidence map›Paper›PMID 35221965›Full record

ArticleCase reports in oncology

Two Cases of ALK-Altered Cancers of Unknown Primary Diagnosed by Immunohistochemistry.

Yoriko Kato, Kazuhiro Shimazu, Koji Fukuda, Taichi Yoshida, Daiki Taguchi, Hanae Shinozaki, Hiroshi Nanjyo, Hiroyuki Shibata

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yoriko KatoDepartment of Clinical Oncology, Akita University, Akita, Japan.
Kazuhiro ShimazuDepartment of Clinical Oncology, Akita University, Akita, Japan.
Koji FukudaDepartment of Clinical Oncology, Akita University, Akita, Japan.
Taichi YoshidaDepartment of Clinical Oncology, Akita University, Akita, Japan.
Daiki TaguchiDepartment of Clinical Oncology, Akita University, Akita, Japan.
Hanae ShinozakiDepartment of Clinical Oncology, Akita University, Akita, Japan.
Hiroshi NanjyoDepartment of Pathology, Akita University Hospital, Akita, Japan.
Hiroyuki ShibataDepartment of Clinical Oncology, Akita University, Akita, Japan.
Akita University · JPAkita University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer of unknown primary (CUP) accounts for 5% of all malignancies. Patients with CUP may live averagely for 8 months after diagnosis, and thus, rapid and reasonable diagnosis is necessary. Among patients with CUP, anaplastic lymphoma kinase (ALK)-overexpressing CUPs, whose primary sites were confirmed to be the lungs (Lung-CUP) by using antibodies against cytokeratin 7, thyroid transcription factor-1, and Napsin A, along with clinical characteristics progressed rapidly and were very sensitive to the ALK inhibitor alectinib. The incidence of ALK alteration in Lung-CUP is 19%. Consequently, it is advised that Lung-CUP be examined by immunohistochemistry (IHC) with an anti-ALK antibody. Alternative examinations, such as a cancer genome test, require as much as 2 months to complete, whereas IHC can be completed within days. In this report, a rapid assessment by IHC led to alectinib treatment, which resulted in good outcomes in 2 cases of Lung-CUP. Alectinib was effective for ALK-altered Lung-CUPs.

Indexed as

ALK inhibitorCancers of unknown primaryImmunohistochemistry

Identifiers

PMID35221965
PMCPMC8832189
OpenAlexW4206126385

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.